patient compliance with their new protease inhibitor, Norvir (ritonavir)

June 1996

Abbott is sending out letters emphasizing patient compliance with their new protease inhibitor, Norvir (ritonavir).

The problem is that patients starting Norvir often develop nausea...diarrhea...and numbness and tingling. This may tempt them to stop the drug or cut back on the dose.

But maintaining therapeutic levels of Norvir is crucial...to suppress HIV and prevent the development of resistance.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote